1. [Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].
- Author
-
Rozet F, Mongiat-Artus P, Ploussard G, Rouprêt M, Cacoub P, Fournier G, and Mathieu R
- Subjects
- Abiraterone Acetate administration & dosage, Adenocarcinoma drug therapy, Adenocarcinoma secondary, Adrenal Cortex Hormones administration & dosage, Androgen Antagonists administration & dosage, Androgens, Antineoplastic Agents, Hormonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Contraindications, Drug, Humans, Immunosuppressive Agents administration & dosage, Male, Meta-Analysis as Topic, Neoplasms, Hormone-Dependent drug therapy, Oxygen therapeutic use, Practice Guidelines as Topic, Prospective Studies, Prostatic Neoplasms drug therapy, Prostatic Neoplasms, Castration-Resistant drug therapy, Randomized Controlled Trials as Topic, Respiration, Artificial, Risk, Abiraterone Acetate adverse effects, Adrenal Cortex Hormones adverse effects, Androgen Antagonists adverse effects, Antineoplastic Agents, Hormonal adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, COVID-19 therapy, Immunosuppressive Agents adverse effects, Pandemics, SARS-CoV-2
- Published
- 2021
- Full Text
- View/download PDF